ERGO OTC
Entia Biosciences, Inc.
1W: +25.0%
1M: +25.0%
3M: +400.0%
YTD: +233.3%
1Y: +900.0%
3Y: -96.9%
5Y: -85.1%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$265K
-23.5% ▼
5Y CAGR: -8.0%
Gross Profit
$174K
-19.4% ▼
5Y CAGR: -8.5%
Operating Income
-$1M
+39.1% ▲
Net Income
-$1M
+38.9% ▲
EPS (Diluted)
$-0.05
+47.3% ▲
EBITDA
-$1M
+37.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $369K | $315K | $656K | $347K | $265K |
| YoY Growth | -8.4% | -14.8% | +108.5% | -47.1% | -23.5% |
| Cost of Revenue | $107K | $131K | $245K | $131K | $91K |
| Gross Profit | $262K | $184K | $411K | $216K | $174K |
| Gross Margin | 70.9% | 58.3% | 62.6% | 62.2% | 65.5% |
| R&D Expenses | $58 | $28 | $25 | $73 | $38K |
| SG&A Expenses | $1M | $3M | $2M | $2M | $1M |
| Operating Expenses | $1M | $3M | $2M | $2M | $1M |
| Operating Income | -$1M | -$3M | -$2M | -$2M | -$1M |
| Operating Margin | -292.7% | -852.0% | -269.8% | -552.3% | -439.7% |
| Interest Expense | $263K | $145K | $340K | $173K | $84K |
| Income Before Tax | -$1M | -$3M | -$2M | -$2M | -$1M |
| Tax Expense | $263K | $145K | $340K | $149K | $77K |
| Net Income | -$2M | -$3M | -$3M | -$2M | -$1M |
| Net Margin | -413.5% | -1032.4% | -401.7% | -694.5% | -554.7% |
| EPS (Diluted) | $-0.21 | $-0.43 | $-0.28 | $-0.10 | $-0.05 |
| EBITDA | -$980K | -$3M | -$2M | -$2M | -$1M |
| Shares Outstanding | 7M | 8M | 9M | 24M | 28M |